摘要
The serological response of the current 2009 H1N1 pandemic influenza monovalent vaccine in children exhibiting high baseline seropositive rate was evaluated though a community-based household study. Seroprotection rate of >90% and seroconversion rate of >50% were observed in children one month after receiving the pandemic vaccine. Among children with low baseline antibody titer, a significant lower seroconversion rate (55%) was observed in children who received seasonal trivalent inactivated vaccine (TIV) prior to pandemic vaccine, when compared with those receiving the pandemic vaccine only (86%). Persistence of antibody against the pandemic influenza virus was observed 6 months after vaccination in >80% of children presenting seroprotective antibody levels.
原文 | 英語 |
---|---|
頁(從 - 到) | 617-623 |
頁數 | 7 |
期刊 | Vaccine |
卷 | 29 |
發行號 | 4 |
DOIs | |
出版狀態 | 已發佈 - 1月 17 2011 |
對外發佈 | 是 |
ASJC Scopus subject areas
- 分子醫學
- 一般免疫學和微生物學
- 一般獸醫學
- 公共衛生、環境和職業健康
- 傳染性疾病